| Nome |
# |
|
Development and validation of a composite disease activity score for juvenile idiopathic arthritis, file e268c4c8-b38e-a6b7-e053-3a05fe0adea1
|
386
|
|
Evidence for Updating the Core Domain Set of Outcome Measures for Juvenile Idiopathic Arthritis: Report from a Special Interest Group at OMERACT 2016, file e268c4cb-97ce-a6b7-e053-3a05fe0adea1
|
197
|
|
The Latvian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR), file e268c4cb-9296-a6b7-e053-3a05fe0adea1
|
114
|
|
Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries, file e268c4cb-522a-a6b7-e053-3a05fe0adea1
|
111
|
|
Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept, file e268c4cb-96fd-a6b7-e053-3a05fe0adea1
|
108
|
|
Molecular mechanisms of autophagic memory in pathogenic T cells in human arthritis, file e268c4cb-a523-a6b7-e053-3a05fe0adea1
|
105
|
|
The Serbian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR), file e268c4cb-928a-a6b7-e053-3a05fe0adea1
|
103
|
|
The Ukrainian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR), file e268c4cb-b6d1-a6b7-e053-3a05fe0adea1
|
99
|
|
The Flemish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR), file e268c4cb-8166-a6b7-e053-3a05fe0adea1
|
98
|
|
The Slovak version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR), file e268c4cb-acf4-a6b7-e053-3a05fe0adea1
|
97
|
|
The Finnish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR), file e268c4cb-ad6a-a6b7-e053-3a05fe0adea1
|
97
|
|
The Greek version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR), file e268c4cb-da5a-a6b7-e053-3a05fe0adea1
|
97
|
|
The Argentinian Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR), file e268c4cb-da6d-a6b7-e053-3a05fe0adea1
|
97
|
|
The Croatian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR), file e268c4cb-ad68-a6b7-e053-3a05fe0adea1
|
96
|
|
The Danish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR), file e268c4cb-dc22-a6b7-e053-3a05fe0adea1
|
96
|
|
The Colombian Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR), file e268c4cb-aec4-a6b7-e053-3a05fe0adea1
|
95
|
|
The American English version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR), file e268c4cb-ad76-a6b7-e053-3a05fe0adea1
|
93
|
|
The Lithuanian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR), file e268c4cb-b888-a6b7-e053-3a05fe0adea1
|
93
|
|
The Russian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR), file e268c4cb-aebf-a6b7-e053-3a05fe0adea1
|
92
|
|
The Egyptian Arabic version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR), file e268c4cb-aef2-a6b7-e053-3a05fe0adea1
|
92
|
|
The Hindi version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR), file e268c4cb-da62-a6b7-e053-3a05fe0adea1
|
92
|
|
The Georgian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR), file e268c4cb-8057-a6b7-e053-3a05fe0adea1
|
88
|
|
The Farsi version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR), file e268c4cb-8052-a6b7-e053-3a05fe0adea1
|
87
|
|
The Libyan Arabic version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR), file e268c4cb-ad6f-a6b7-e053-3a05fe0adea1
|
87
|
|
The German version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR), file e268c4cb-da5c-a6b7-e053-3a05fe0adea1
|
87
|
|
The Mexican Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR), file e268c4cb-dc2a-a6b7-e053-3a05fe0adea1
|
86
|
|
The Swiss French version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR), file e268c4cb-e6e7-a6b7-e053-3a05fe0adea1
|
86
|
|
The Portuguese version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR), file e268c4cb-804c-a6b7-e053-3a05fe0adea1
|
85
|
|
Filling the Gap: Toward a Disease Activity Tool for Systemic Juvenile Idiopathic Arthritis, file e268c4cb-97cd-a6b7-e053-3a05fe0adea1
|
85
|
|
The Paraguayan Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR), file e268c4cb-aebd-a6b7-e053-3a05fe0adea1
|
85
|
|
A child with a novel ACAN missense variant mimicking a septic arthritis, file e268c4cb-89f3-a6b7-e053-3a05fe0adea1
|
84
|
|
The Hungarian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR), file e268c4cb-ad7e-a6b7-e053-3a05fe0adea1
|
84
|
|
The Turkish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR), file e268c4cb-da60-a6b7-e053-3a05fe0adea1
|
84
|
|
The British English version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR), file e268c4cb-799a-a6b7-e053-3a05fe0adea1
|
83
|
|
The Italian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR), file e268c4cb-9ffd-a6b7-e053-3a05fe0adea1
|
83
|
|
Cross-cultural adaptation and psychometric evaluation of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) in 54 languages across 52 countries: review of the general methodology, file e268c4cb-a000-a6b7-e053-3a05fe0adea1
|
83
|
|
The Czech version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR), file e268c4cb-b6cc-a6b7-e053-3a05fe0adea1
|
83
|
|
The Swedish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR), file e268c4cb-c9f6-a6b7-e053-3a05fe0adea1
|
83
|
|
A prediction rule for lack of achievement of inactive disease with methotrexate as the sole disease-modifying antirheumatic therapy in juvenile idiopathic arthritis, file e268c4cb-4e78-a6b7-e053-3a05fe0adea1
|
82
|
|
The Algerian Arabic version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR), file e268c4cb-ba5a-a6b7-e053-3a05fe0adea1
|
82
|
|
The Arabic version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR), file e268c4cb-e6de-a6b7-e053-3a05fe0adea1
|
81
|
|
The Dutch version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR), file e268c4cb-c9f0-a6b7-e053-3a05fe0adea1
|
80
|
|
The Slovene version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR), file e268c4cb-c9f4-a6b7-e053-3a05fe0adea1
|
80
|
|
The Chilean Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR), file e268c4cb-aec1-a6b7-e053-3a05fe0adea1
|
79
|
|
The Omani Arabic version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR), file e268c4cb-ba61-a6b7-e053-3a05fe0adea1
|
79
|
|
The Norwegian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR), file e268c4cb-d502-a6b7-e053-3a05fe0adea1
|
79
|
|
The Polish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR), file e268c4cb-803f-a6b7-e053-3a05fe0adea1
|
78
|
|
The Afrikaans version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR), file e268c4cb-ad7c-a6b7-e053-3a05fe0adea1
|
78
|
|
The Castilian Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR), file e268c4cb-da5e-a6b7-e053-3a05fe0adea1
|
78
|
|
The Bulgarian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR), file e268c4cb-ad73-a6b7-e053-3a05fe0adea1
|
77
|
|
Disease activity and damage in juvenile idiopathic arthritis: Methotrexate era versus biologic era, file e268c4cb-3f40-a6b7-e053-3a05fe0adea1
|
76
|
|
The Canadian English and French versions of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR), file e268c4cb-ad71-a6b7-e053-3a05fe0adea1
|
76
|
|
The Ecuadorian Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR), file e268c4cb-8055-a6b7-e053-3a05fe0adea1
|
75
|
|
The Thai version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR), file e268c4cb-c9b6-a6b7-e053-3a05fe0adea1
|
75
|
|
The French version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR), file e268c4cb-e6ed-a6b7-e053-3a05fe0adea1
|
73
|
|
Juvenile Idiopathic Arthritis: Diagnosis and Treatment, file e268c4cb-5230-a6b7-e053-3a05fe0adea1
|
72
|
|
The Hebrew version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR), file e268c4cb-e6ea-a6b7-e053-3a05fe0adea1
|
72
|
|
The Brazilian Portuguese version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR), file e268c4cb-9298-a6b7-e053-3a05fe0adea1
|
71
|
|
The Romanian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR), file e268c4cb-c9e9-a6b7-e053-3a05fe0adea1
|
70
|
|
IL-1 Inhibition in Systemic Juvenile Idiopathic Arthritis, file e268c4cb-787c-a6b7-e053-3a05fe0adea1
|
65
|
|
The Estonian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR), file e268c4cb-ba5f-a6b7-e053-3a05fe0adea1
|
64
|
|
Clinical outcome measures in juvenile idiopathic arthritis, file e268c4cb-4de8-a6b7-e053-3a05fe0adea1
|
60
|
|
TCR repertoire sequencing identifies synovial Treg cell clonotypes in the bloodstream during active inflammation in human arthritis, file e268c4cb-96fa-a6b7-e053-3a05fe0adea1
|
51
|
|
Preface, file e268c4cb-d4fe-a6b7-e053-3a05fe0adea1
|
38
|
|
Drivers of non-zero physician global scores during periods of inactive disease in juvenile idiopathic arthritis, file e268c4ce-9a21-a6b7-e053-3a05fe0adea1
|
14
|
|
Neutrophil Extracellular Traps in Systemic Lupus Erythematosus Stimulate IgG2 Production From B Lymphocytes, file e268c4cd-cfa9-a6b7-e053-3a05fe0adea1
|
9
|
|
Timely Recognition and Early Multi-Step Antinflammatory Therapy May Prevent ICU Admission of Patients With MIS-C: Proposal for a Severity Score, file e268c4ce-9529-a6b7-e053-3a05fe0adea1
|
4
|
|
Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study, file e268c4cb-0ed0-a6b7-e053-3a05fe0adea1
|
2
|
|
A Meta-Analysis to Estimate the Placebo Effect in Randomized Controlled Trials in Juvenile Idiopathic Arthritis, file e268c4cb-7bb8-a6b7-e053-3a05fe0adea1
|
2
|
|
Critical role of STIR MRI in early detection of post-streptococcal periostitis with dysproteinaemia (Goldbloom's syndrome), file e268c4cb-96fe-a6b7-e053-3a05fe0adea1
|
2
|
|
MRI versus conventional measures of disease activity and structural damage in evaluating treatment efficacy in juvenile idiopathic arthritis., file e268c4c8-b1e2-a6b7-e053-3a05fe0adea1
|
1
|
|
Whole-body MRI in the assessment of disease activity in juvenile dermatomyositis, file e268c4c8-b3ee-a6b7-e053-3a05fe0adea1
|
1
|
|
Intra-articular corticosteroids versus intra-articular corticosteroids plus methotrexate in oligoarticular juvenile idiopathic arthritis: a multicentre, prospective, randomised, open-label trial, file e268c4c8-b442-a6b7-e053-3a05fe0adea1
|
1
|
|
Information technology in paediatric rheumatology, file e268c4cb-3f44-a6b7-e053-3a05fe0adea1
|
1
|
|
Current Research in Outcome Measures for Pediatric Rheumatic and Autoinflammatory Diseases, file e268c4cb-3f4c-a6b7-e053-3a05fe0adea1
|
1
|
|
Recent therapeutic advances in juvenile idiopathic arthritis, file e268c4cb-44ba-a6b7-e053-3a05fe0adea1
|
1
|
|
The conundrum of juvenile psoriatic arthritis, file e268c4cb-7dfd-a6b7-e053-3a05fe0adea1
|
1
|
|
The EULAR Outcome Measures Library: development and an example from a systematic review for systemic lupus erythematous instruments, file e268c4cb-7dff-a6b7-e053-3a05fe0adea1
|
1
|
|
Development and testing of a hybrid measure of muscle strength in juvenile dermatomyositis for use in routine care, file e268c4cb-97d2-a6b7-e053-3a05fe0adea1
|
1
|
|
Open issues in the assessment and management of pain in juvenile idiopathic arthritis, file e268c4cb-9d4a-a6b7-e053-3a05fe0adea1
|
1
|
|
Development and validation of a composite disease activity score for measurement of muscle and skin involvement in juvenile dermatomyositis, file e268c4cb-a004-a6b7-e053-3a05fe0adea1
|
1
|
|
Treating juvenile idiopathic arthritis to target: Recommendations of an international task force, file e268c4cb-a04f-a6b7-e053-3a05fe0adea1
|
1
|
|
Predictors of effectiveness of anakinra in systemic juvenile idiopathic arthritis, file e268c4cb-ad09-a6b7-e053-3a05fe0adea1
|
1
|
|
Advances in biomarkers for paediatric rheumatic diseases, file e268c4cb-bde4-a6b7-e053-3a05fe0adea1
|
1
|
|
Defining criteria for disease activity states in juvenile idiopathic arthritis, file e268c4cb-bdea-a6b7-e053-3a05fe0adea1
|
1
|
|
Unraveling the phenotypic variability of juvenile idiopathic arthritis across races or geographic areas - Key to understanding etiology and genetic factors?, file e268c4cb-d1f4-a6b7-e053-3a05fe0adea1
|
1
|
|
Establishing an Updated Core Domain Set for Studies in Juvenile Idiopathic Arthritis: A Report from the OMERACT 2018 JIA Workshop, file e268c4cc-3eaa-a6b7-e053-3a05fe0adea1
|
1
|
|
Disease activity, overweight, physical activity and screen time in a cohort of patients with juvenile idiopathic arthritis, file e268c4cc-4046-a6b7-e053-3a05fe0adea1
|
1
|
|
Transitional care of young people with juvenile idiopathic arthritis in Italy: results of a Delphi consensus survey, file e268c4cc-41e7-a6b7-e053-3a05fe0adea1
|
1
|
|
Development and testing of reduced versions of the MMT-8 in juvenile dermatomyositis, file e268c4cd-cec8-a6b7-e053-3a05fe0adea1
|
1
|
|
Analysis of arthritis flares after achievement of inactive disease with methotrexate monotherapy in juvenile idiopathic arthritis, file e268c4cd-f310-a6b7-e053-3a05fe0adea1
|
1
|
|
Determinants of discordance between criteria for inactive disease and low disease activity in juvenile idiopathic arhritis, file e268c4ce-c368-a6b7-e053-3a05fe0adea1
|
1
|
| Totale |
5.847 |